- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00559078
Qualitative Research on Women With Congenital Adrenal Hyperplasia (CAH)
November 6, 2009 updated by: Lehigh University
Health-related Quality of Life, Mental Health and Psychotherapeutic Considerations for Women Diagnosed With a Disorder of Sexual Development: Congenital Adrenal Hyperplasia
This qualitative interview-based study will investigate the impact that living with congenital adrenal hyperplasia has for women in the following areas: health-related quality of life (HRQL), psychological health, and health-seeking behaviors.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Congenital Adrenal Hyperplasia is a chronic-illness requiring life-long treatment and is caused by an inherited enzyme deficiency that leads to an overproduction of hormones produced by the adrenal glands, which in turn, masculinizes the female genitalia before birth.
While the mechanisms by which CAH influences physiological development are understood, the impact of this hormonal elevation on health-related quality of life (HRQL), psychological health, and health-seeking behaviors is less clear.
This study is guided by three research questions: (1) how does CAH influence HRQL domains (physical, functional, emotional and interpersonally), (2) how does CAH influence the mental health of women diagnosed with CAH, and (3) how does CAH influence decisions to seek help from a counselor?
Semi-structured qualitative interviews will be conducted with women with CAH.
Interviews will be analyzed through the Consensual Qualitative Research (CQR) methodology.
Study Type
Observational
Enrollment (Anticipated)
16
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, United States, 18015
- Lehigh University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
25 years to 55 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Sampling Method
Non-Probability Sample
Study Population
Women diagnosed with CAH (either simple-virilizing or salt-losing types) living in the United States
Description
Inclusion Criteria:
- 46XX, Females
- Diagnosed by a physician with CAH (either simple-virilizing or salt-losing types)
- Willing to complete a brief demographic questionnaire and participate in an hour long telephone interview
Exclusion Criteria:
- Non-classical or late-onset CAH
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
CAH
Women diagnosed with CAH (either simple virilizing or salt-losing)
|
Hour-long, qualitative, phone interview
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Telephone interview consisting of approximately 7 open ended questions addressing domains of HRQL, Mental Health and Support
Time Frame: 1 hour
|
1 hour
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Demographic Questionnaire
Time Frame: 15 minutes
|
15 minutes
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Matthew A Malouf, BA, Lehigh University Counseling Psychology
- Principal Investigator: Arpana G Inman, Lehigh University Counseling Psychology
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2007
Study Completion (Actual)
May 1, 2009
Study Registration Dates
First Submitted
November 15, 2007
First Submitted That Met QC Criteria
November 15, 2007
First Posted (Estimate)
November 16, 2007
Study Record Updates
Last Update Posted (Estimate)
November 9, 2009
Last Update Submitted That Met QC Criteria
November 6, 2009
Last Verified
November 1, 2009
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Metabolic Diseases
- Endocrine System Diseases
- Gonadal Disorders
- Disorders of Sex Development
- Urogenital Abnormalities
- Congenital Abnormalities
- Genetic Diseases, Inborn
- Metabolism, Inborn Errors
- Adrenal Gland Diseases
- Steroid Metabolism, Inborn Errors
- Hyperplasia
- Adrenal Hyperplasia, Congenital
- Adrenogenital Syndrome
- Adrenocortical Hyperfunction
Other Study ID Numbers
- 1-Malouf
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.